clinical trial · NCT07925190
A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
Beijing InnoCare Pharma Tech Co., Ltd.·phase3·recruiting·n = 318
Acute Myeloblastic LeukemiaMesutoclax (ICP-248)Azacitidine (AZA)Venetoclax
brief summary
A Phase III study comparing Mesutoclax + azacitidine versus venetoclax + azacitidine in newly diagnosed acute myeloid leukemia (AML) patients
started
Nov 3, 2026
primary completion
Dec 1, 2029
completion
Jun 1, 2030
last updated
Nov 13, 2026
official title
A Randomized, Open-label, Multicenter Phase III Study of Mesutoclax Combined With Azacitidine Versus Venetoclax Combined With Azacitidine in the Treatment of Treatment-naive Acute Myeloid Leukemia (AML) Who Are Elderly or Ineligible for Intensive Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol